Preoperative Red Cell Distribution Width as a Predictor of Mortality in Patients After Coronary Artery Bypass Grafting



Similar documents
Prognostic impact of uric acid in patients with stable coronary artery disease

Main Effect of Screening for Coronary Artery Disease Using CT

ECG may be indicated for patients with cardiovascular risk factors

Cardiac Rehabilitation An Underutilized Class I Treatment for Cardiovascular Disease

Steven J. Yakubov, MD FACC For the CoreValve US Clinical Investigators

Measure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care

Cardiac Rehabilitation The Best Medicine for Your CAD Patients. James A. Stone

Protocol. Cardiac Rehabilitation in the Outpatient Setting

Coronary Artery Disease leading cause of morbidity & mortality in industrialised nations.

Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease

Causes of Anemia in Patients with Heart Failure. Adriaan Voors, MD, PhD, Cardiologist Professor of Cardiology, UMC Groningen, Netherlands

Cilostazol versus Clopidogrel after Coronary Stenting

Cardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg

Listen to your heart: Good Cardiovascular Health for Life

Albumin and All-Cause Mortality Risk in Insurance Applicants

Impact of Massachusetts Health Care Reform on Racial, Ethnic and Socioeconomic Disparities in Cardiovascular Care

DISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD

Coronary Heart Disease (CHD) Brief

Medical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South

How can registries contribute to guidelines? Nicolas DANCHIN, HEGP, Paris

Atherosclerosis of the aorta. Artur Evangelista

06 Validation of risk prediction model

LEADERS: 5-Year Follow-up

Journal of the American College of Cardiology Vol. 38, No. 2, by the American College of Cardiology ISSN /01/$20.

Antonio Colombo MD on behalf of the SECURITY Investigators

After acute myocardial infarction, diabetes CARDIAC OUTCOMES AFTER MYOCARDIAL INFARCTION IN ELDERLY PATIENTS WITH DIABETES MELLITUS

The Initial and 24 h (After the Patient Rehabilitation) Deficit of Arterial Blood Gases as Predictors of Patients Outcome

Heart Center Packages

RDW-- Interpreting the Full Blood Count

Barriers to Healthcare Services for People with Mental Disorders. Cardiovascular disorders and diabetes in people with severe mental illness

ACUTE CORONARY SYNDROME By Dr wasfi al abadi md jbc, dr walid sawalha mbbs mrcp jbc

Elevated heart rate at twelve months after heart transplantation is an independent predictor of long term mortality

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR CARDIOVASCULAR DISEASE PREVENTION

RATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY. Charles Jazra

Rheumatoid Factor is a Strong Risk Factor for Coronary Artery Disease in Men with Metabolic Syndrome

Is Stenting or Coronary Artery By-pass Grafting the Better Treatment for This Patient?

Objectives. Preoperative Cardiac Risk Stratification for Noncardiac Surgery. History

HA Territory-wide PCI Audit

Cardiac Rehabilitation: Strategies Approaching 2020

The largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November :38

Results of streamlined regional ambulance transport and subsequent treatment of acute abdominal aortic aneurysm

Cardiovascular disease is the leading cause of morbidity

FULL COVERAGE FOR PREVENTIVE MEDICATIONS AFTER MYOCARDIAL INFARCTION IMPACT ON RACIAL AND ETHNIC DISPARITIES

Determinants of duration of ICU stay after coronary artery bypass graft surgery

Cardiac Rehabilitation: An Under-utilized Resource Making Patients Live Longer, Feel Better

COMMITTEE FOR HUMAN MEDICINAL PRODUCTS (CHMP) DRAFT GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR CARDIOVASCULAR DISEASE PREVENTION

FFR CT : Clinical studies

The return of myocardial ischemia after coronary artery

Stent for Life Initiative How can we improve system delay and patients delay in STEMI

Specific Basic Standards for Osteopathic Fellowship Training in Cardiology

Guide to Biostatistics

PHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES.

Mitral Valve Repair versus Replacement for Severe Ischemic Mitral Regurgitation. Michael Acker, MD For the CTSN Investigators AHA November 2013

Cardiac Rehabilitation (Outpatient Phase II) Corporate Medical Policy. Medical Policy

Cardiovascular Endpoints

Summary Evaluation of the Medicare Lifestyle Modification Program Demonstration and the Medicare Cardiac Rehabilitation Benefit

on behalf of the AUGMENT-HF Investigators

Creating a Hybrid Database by Adding a POA Modifier and Numerical Laboratory Results to Administrative Claims Data

Malmö Preventive Project. Cardiovascular Endpoints

For the NXT Investigators

Osama Jarkas. in Chest Pain Patients. STUDENT NAME: Osama Jarkas DATE: August 10 th, 2015

Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group

If several different trials are mentioned in one publication, the data of each should be extracted in a separate data extraction form.

Patients with end-stage renal disease (ESRD) are at high

3/2/2010 Post CABG R h e bili a i tat on Ahmed Elkerdany Professor o f oof C ardiac Cardiac Surgery Ain Shams University 1

BASIC STANDARDS FOR RESIDENCY TRAINING IN CARDIOLOGY

Automatic External Defibrillators

Zhongmin Li, PhD University of California, Davis School of Medicine

Cardiovascular Endpoints

The Role of Insurance in Providing Access to Cardiac Care in Maryland. Samuel L. Brown, Ph.D. University of Baltimore College of Public Affairs

INTRODUCTION TO EECP THERAPY

Specialty Excellence Award and America s 100 Best Hospitals for Specialty Care Methodology Contents

THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT

Cardiac Rehabilitation CARDIAC REHABILITATION HS-091. Policy Number: HS-091. Original Effective Date: 3/16/2009

Your Guide to Express Critical Illness Insurance Definitions

PRECOMBAT Trial. Seung-Whan Lee, MD, PhD On behalf of the PRECOMBAT Investigators

The Canadian Association of Cardiac

Your Life Your Health Cariodmetabolic Risk Syndrome Part VII Inflammation chronic, low-grade By James L. Holly, MD The Examiner January 25, 2007

R.P. Zecchin*, J. Baihn, Y.Y. Chai, J. Hungerford, G. Lindsay, M. Owen, J. Thelander, D.L. Ross, C. Chow, A.R. Denniss. Westmead Hospital, Sydney,

6/5/2014. Objectives. Acute Coronary Syndromes. Epidemiology. Epidemiology. Epidemiology and Health Care Impact Pathophysiology

Stroke Risk Scores. CHA 2 DS 2 -VASc. CHA 2 DS 2 -VASc Scoring Table 2

Physician and other health professional services

Inconsistencies in the Use of Cardiac Biomarkers or Echocardiography in Patients with Acute Non-Massive Pulmonary Embolism

Utilization Review Cardiac Rehabilitation Services: Underutilized

Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results

The Cardiac Society of Australia and New Zealand

25-hydroxyvitamin D: from bone and mineral to general health marker

Endoskopische Venenentnahme der V. saphena in der koronaren Bypasschirurgie - Aktuelle Datenlage - Dr. med. Stefanie Reutter

The WHI 12 Years Later: What Have We Learned about Postmenopausal HRT?

Statins and Risk for Diabetes Mellitus. Background

Psoriasis Co-morbidities: Changing Clinical Practice. Theresa Schroeder Devere, MD Assistant Professor, OHSU Dermatology. Psoriatic Arthritis

Atrial Fibrillation 2014 How to Treat How to Anticoagulate. Allan Anderson, MD, FACC, FAHA Division of Cardiology

A randomized, controlled trial comparing the efficacy of carvedilol vs. metoprolol in the treatment of atrial fibrillation

Omega-3 fatty acids improve the diagnosis-related clinical outcome. Critical Care Medicine April 2006;34(4):972-9

Comparison of Clinical Outcomes in Patients Who Underwent Bare Metal Coronary Stenting Versus Coronary By-pass Surgery

NIHI Big Data in Healthcare Research Case Study

Malmö Preventive Project. Cardiovascular Endpoints

CARDIAC CARE. Giving you every advantage

The ACC 50 th Annual Scientific Session

Use of Glycated Hemoglobin and Microalbuminuria in the Monitoring of Diabetes Mellitus

Transcription:

ORİJİNAL ARAŞTIRMA ORIGINAL INVESTIGATION l doi: 10.5578/kkd.460 Preoperative Red Cell Distribution Width as a Predictor of Mortality in Patients After Coronary Artery Bypass Grafting Koroner Arter Baypas Cerrahisi Sonrası Hastalarda Mortalite Belirteci Olarak Preoperatif Kırmızı Küre Dağılım Hacmi İrfan Taşoğlu 1, Osman Turak 2, Fırat Özcan 2, Yunus Nazlı, Ersin Kadiroğulları 1, Murat Songur 1, Doğan Sert 1, Metin Yılmaz 1, Aslı Demir 4, Alper Uzun 5 1 Department of Cardiovascular Surgery, High Specialization Training and Research Hospital, Ankara, Turkey 1 Ankara Türkiye Yüksek İhtisas Eğitim ve Araştırma Hastanesi, Kalp ve Damar Cerrahisi Kliniği, Ankara, Türkiye 2 Department of Cardiology, High Specialization Training and Research Hospital, Ankara, Turkey 2 Ankara Türkiye Yüksek İhtisas Eğitim ve Araştırma Hastanesi, Kardiyoloji Kliniği, Ankara, Türkiye Department of Cardiovascular Surgery, Faculty of Medicine, Fatih University, Ankara, Turkey Fatih Üniversitesi Tıp Fakültesi, Araştırma ve Uygulama Hastanesi, Kalp ve Damar Cerrahisi Kliniği, Ankara, Türkiye 4 Department of Anesthesiology, High Specialization Training and Research Hospital, Ankara, Turkey 4 Ankara Türkiye Yüksek İhtisas Eğitim ve Araştırma Hastanesi, Anesteziyoloji Kliniği, Ankara, Türkiye 5 Department of Cardiovascular Surgery, Ankara Training and Research Hospital, Ankara, Turkey 5 Ankara Eğitim ve Araştırma Hastanesi, Kalp ve Damar Cerrahisi Kliniği, Ankara, Türkiye Yazışma Adresi/ Correspondence Dr. İrfan Taşoğlu Ankara Türkiye Yüksek İhtisas Eğitim ve Araştırma Hastanesi, Kalp ve Damar Cerrahisi Kliniği Ankara-Türkiye e-posta irfantasoglu@yahoo.com ABSTRACT Introduction: We hypothesized that the red cell distribution width (RDW) would predict the outcome of surgical revascularization of patients with coronary artery disease. Materials and Methods: Ninety four patients with severe coronary artery disease who underwent coronary artery bypass grafting were included in this study. A total of 94 patients were divided into tertiles based on their preprocedural RDW (mean RDW: tertile 1, 12.68 ± 0.60; tertile 2: 1.64 ± 0.49; tertile, 16.47 ± 2.04). Results: There were a total of 18 (19.1%) deaths over a mean follow-up of 51 months. Patients with a high RDW showed the highest mortality (4%) as compared to patients with medium (10%) and low RDW (1%). In multivariable regression modeling, RDW > 14.6 was a significant independent predictor of five year outcome in mortality. Conclusion: In conclusion, elevated preprocedural RDW in patients undergoing coronary artery bypass grafting is associated with increased risk of long-term mortality. Key Words: Coronary artery bypass grafting; mortality; morbidity; red cell distribution width. Received: 2.11.2012 l Accepted: 08.12.2012 1

Preoperative Red Cell Distribution Width as a Predictor of Mortality in Patients After Coronary Artery Bypass Grafting Koroner Arter Baypas Cerrahisi Sonrası Hastalarda Mortalite Belirteci Olarak Preoperatif Kırmızı Küre Dağılım Hacmi ÖZET Giriş: Biz kırmızı küre dağılım hacmi (RDW) nin koroner arter hastalarında cerrahi revaskülarizasyon sonrası sonuçlarda belirleyici olduğunu düşündük. Gereç ve Yöntem: Ciddi koroner arter hastalığı olan koroner baypas cerrahisi geçirmiş 94 hasta çalışmaya dahil edildi. Toplam 94 hasta RDW değerlerine göre üç gruba ayrıldı (mean RDW: tertile 1, 12.68 ± 0.60; tertile 2: 1.64 ± 0.49; tertile, 16.47 ± 2.04). Bulgular: Ortalama 51 aylık takipte toplam 18 (%19.1) ölüm gözlendi. Yüksek RDW li hastalar orta (%10) ve düşük (%1) RDW li hastalara kıyasla yüksek mortalite gösterdi. Değişkenli regresyon analizinde RDW > 14.6 beş yıllık sonuçlar için önemli bağımsız risk faktörüdür. Sonuç: Sonuç olarak, koroner baypas cerrahisi geçirmiş hastaların preoperatif yüksek RDW değeri artmış uzun dönem mortalite riski ile ilişkilidir. Anahtar Kelimeler: Koroner arter baypas; mortalite; morbidite; kırmızı küre dağılım hacmi. Geliş Tarihi: 2.11.2012 l Kabul Tarihi: 08.12.2012 IntroductIon The profile of patients candidate for coronary artery bypass grafting (CABG) is continuously changing and older patients share a large part with associated comorbidities, such as diabetes mellitus, hypertension, smoking, and peripheral vascular disease. Although several methods of risk assessment, such as the European System for Cardiac Operative Risk Evaluation (EuroSCORE), are widely used, they are imperfect (1). There remains, therefore, a need for additional methods for risk stratification, particularly if easily obtained and widely available. Especially in the last decade it was shown that red cell distribution width (RDW) had an important effect on congestive heart failure, coronary artery disease, morbidity and mortality after percutaneous intervention (2-4). The potential use of preoperative RDW in the risk stratification of patients with coronary artery disease to identify postoperative mortality has not been studied yet. We aimed to investigate the relation between preoperative RDW and postoperative all cause mortality in patients with coronary artery disease along with other initial parameters. MATERIALS and Methods We randomized widespread coronary artery disease patients for our study because RDW in coronary artery disease is closely related to mortality, cardiovascular events and the progress of coronary atherosclerosis. Between March 200 and April 2009, 108 individuals underwent concomitant coronary artery bypass grafting. Demographic characteristics, medical records, laboratory studies and outcome data were collected by the research team using a standardized database (Table 1). The local ethics committee approved the study protocol. 2 Exclusion criteria included being 85 years or older, emergent surgery, additional major cardiac procedure, previous treatment for anemia, recent transfusion, clinical evidence of active infection, hematologic proliferative diseases, steroid therapy or chemotherapy around the index diagnosis or unavailable complete blood cell count or medical records. According to these criteria, 14 patients were excluded. Thus 94 patients were included the study. Patients were followed up in outpatient clinics following discharge. The primary end point, all-cause five year mortality, was obtained from electronic medical records and the Social Security Death Index. Laboratory All analyses used the blood sample obtained immediately before surgery. Levels of hemoglobin (Hb), RDW, and white blood cells (WBC) were measured using a Siemens Advia 2120 analyzer. The normal reference range for RDW in our laboratory was 11.5% to 14.5%. Anemia was defined as hemoglobin < 1 g/dl in men and < 12 g/dl in women. Statistics The primary end-point was death from any cause within five years of surgery. The effect of RDW on outcome was studied by constructing a receiver operating characteristic (ROC) curve with all cause mortality as the primary variable (Figure 1). Continuous data were presented as mean ± SD. The study population was grouped into tertiles according to the admission RDW value. Comparison between patient groups were made using chisquare tests for categorical variables, independent-samples Student s t tests for normally distributed continuous variables, and Mann-Whitney U tests when the distribu-

Taşoğlu İ, Turak O, Özcan F, Nazlı Y, Kadiroğulları E, Songur M, Sert D, Yılmaz M, Demir A, Uzun A. Table 1. Patient demographic, clinical and hematochemical characteristics. Baseline characteristics of patients, divided according to red blood cell distribution width Risk factors Tertile 1 12.0-1.0 n= 1 Tertile 2 1.0-14.6 n= 1 Tertile 14.6-22.0 n= 2 p Age (year) 57.2 ± 9.6 61.5 ± 8.51 61.6 ± 1.05 0.184 Male 27 (88%) 26 (94%) 20 (6%) 0.057 Current smoke 10 (2%) 8 (25%) 7 (21%) 0.65 Diabetes mellitus 10 (2%) 4 (12%) 15 (46%) 0.01 Hypertension 16 (51%) 11 (5%) 16 (50%) 0.8 Obesity 2 (6%) 1 (%) 2 (6%) 0.82 Hyperlipidemia 7 (22%) 6 (19%) 6 (18%) 0.92 Stable angina pectoris 18 (58%) 1 (%) 1 (40%) 0.1 Unstable angina pectoris 1 (%) 2 (6%) (9%) 0.82 Previous myocardial infarction 4 (12%) 6 (19%) 6 (19%) 0.61 Presence of anemia 1 (%) 4 (12%) 14 (44%) < 0.001 Estimated LVEF % 57. ± 12.0 58.4 ± 4.0 7 (21%) 0.48 NYHA I or II 11 (5%) 1 (42%) 14 (44%) 0.2 NYHA III or IV 20 (65%) 18 (58%) 18 (56%) 0.9 EuroSCORE 4 (2-6) 4 (2-6) 6 (4-8) < 0.001 Congestive heart failure 9 (29%) 8 (25%) 11 (4%) 0.9 Operative data Postoperative intraaortic balloon pump (9%) 1 (%) 5 (15%) 0. LMCA disease 1 (%) 0 (0%) 1 (%) 0. No. of bypass grafts 2.6 ± 0.62 2.6 ± 0.59 2.8 ± 0.65 0.61 Cross-clamp time (min) 60.21 ± 2.41 61.4 ± 27.8 50.52 ± 2.7 0.14 Bypass time (min) 87.21 ± 50.61 96.9 ± 6.68 84.58 ± 49.92 0.51 Internal mammary artery used 28 (90%) 28 (90%) 0 (9%) 0.48 Postoperative data Drainage (ml) 665.48 ± 86.9 702.5 ± 98.291 71.25 ± 702.50 0.89 ICU time (hour) 12.9 ± 16.64 12.46 ±10.7 18.0 ± 24.5 0.20 Mechanical ventilation (hour) 5.0 ± 11.8 2.0 ±.8 2.4 ± 2.1 0.18 Hospital time (day) 1.0 ± 19.01 7. ± 8.4 7.5 ± 4. 0.11 Hospital exitus (9%) 1 (%) 2 (6%) 0.59 Totally exitus 4 (12%) (9%) 11 (4%) 0.02 Preoperative laboratory RDW (%) 12.68 ± 0.60 1.64 ± 0.49 16.47 ± 2.04 < 0.001 Hemoglobin (mg/dl) 14.54 ± 1.22 1.76 ± 2.25 12.04 ± 2.0 < 0.001 WBC (10 /mm ) 7.8 ± 2.1 8.54 ± 2.5 9.1 ±.01 0.14 Creatinine (mg/dl) 0.87 ± 0.14 1.07 ± 1.1 1.25 ± 1.27 0.8 Urea (mg/dl) 40 ± 8.07 44.4 ± 26.8 50. ± 27.65 0.2 Percentages refer to patients with data available. LVEF: Left ventricular ejection fraction; NYHA: New York Heart Association; LMCA: Left main coronary artery; LAD: Left anterior descending coronary artery; RCA: Right coronary artery, ICU: Intensive care unit, RDW: Red cell distribution width, WBC: White blood count.

Preoperative Red Cell Distribution Width as a Predictor of Mortality in Patients After Coronary Artery Bypass Grafting Koroner Arter Baypas Cerrahisi Sonrası Hastalarda Mortalite Belirteci Olarak Preoperatif Kırmızı Küre Dağılım Hacmi Mortality p < 0.001 1.00 15 p < 0.001 0.75 10 5 p > 0.05 Sensitivity 0.50 0 tertiles deaths 1 2 4 11 0.25 RDW > 14.6 C statistic: 0.7 Sensitivity 66% Specificity 7% Figure 1. Red blood cell distribution width measures as a function of mortality at five year after CABG. tion was skewed. Categorical variables were summarized as percentages. Correlations between mortality and other continuous variables were studied using Pearson s and Spearman s correlation. Potential prognostic factors were entered into univariate logistic regression models of five year mortality. Significant univariate correlates were then entered into a reverse stepwise multivariate logistic regression model to test for independence. 1.00 Multivariable logistic regression analysis was applied to identify whether RDW level on admission was independently associated with any cause mortality. Analyses were performed 0.75 using SPSS. Results The study cohort was predominantly male (%77) with a 0.50 median age of 59 ± 10. years (Table 1). Patients included in this study have atherosclerosis documented with coronary angiography in.2 ± 1.8 coronary RDW > 14.6 vessels; 2.7 ± 1. C statistic: 0.7 are grafted 0.25 and one of these vessels Sensitivity had 66% always severe atherosclerosis. Specificity 7% Overall, there were a total of 18 (19.1%) deaths from any cause 0.00 within five years of surgery, and patients with a high RDW 0.00 showed 0.25 the highest 0.50 mortality 0.75 (n= 11, 4%) 1.00 as compared to patients with medium Specificity(n=, 10%) and low RDW (n= 4, RDW: 1%) Red (Table Cell distribution 1, p= 0.02). width. Furthermore, the difference between mortality in high RDW with intermediate and low RDW was also statistically significant (Figure 2). Baseline characteristics of patients divided according to three tertiles of RDW are presented in Table 1. There were no statistical differences in age and gender between groups. Sensitivity 0.00 0.00 0.25 0.50 0.75 1.00 Specificity RDW: Red Cell distribution width. Figure 2. A receiver operating characteristic curve for red cell distribution width versus mortality. No difference was observed between groups with respect to the risk factors, medical history, and preoperative, operative, and postoperative data, but diabetes mellitus (p= 0.01), presence of anemia (p < 0.001), EuroScore (p < 0.001), Hb (p < 0.001), RDW (p < 0.001) were higher in tertile. In our patients, all cause mortality was correlated with admission (first ever obtained) RDW > 14.6 (r= 0.405, p< 0.001), Hb (r = -0.292, p= 0.004), presence of anemia (r= 0.9, p< 0.001), urea (r= 0.22, p= 0.002), and age (r= 0.279, p= 007). There were no significant correlations between all cause mortality and the other data (p > 0.05). In univariate logistic regression, age, preoperative Hb, preoperative RDW > 14.6 and, EuroScore were all significantly associated with five year mortality. In multivariate regression modeling, EuroScore and preoperative RDW > 14.6 independently predicted survival in 5 years. In multivariable regression modeling, RDW > 14.6 was a significant independent predictor of five year outcome in mortality (HR =.7 per 1% increase in RDW; 95% CI: 1.08-12.8; p= 0.0) (Table 2). DIscussIon RDW reflects the variability in size of circulating red blood cells and, when elevated, defines the state of anisocytosis. Recently, RDW, a recently described novel risk marker, has been shown to be predictive of morbidity and mortality in variety of cardiovascular settings, includ- 4

Taşoğlu İ, Turak O, Özcan F, Nazlı Y, Kadiroğulları E, Songur M, Sert D, Yılmaz M, Demir A, Uzun A. Table 2. Results of multivariate logistic regression models Multivariate analysis Variable HR 95% CI p Age 1.05 0.9-1.1 0.1 Hemoglobin (g/dl) 0.9 0.6-1.2 0.4 RDW > 14.6.7 1.08-12.8 0.0 EuroSCORE 5.1 1.2-20.2 < 0.001 HR: Hazard Ratio, Cl: Confidence interval, RDW: Red cell distribution width. ing heart failure, stable coronary artery disease, and acute myocardial infarction (2-4). We assessed the effect of RDW on all-cause mortality in patients after CABG. Very importantly, we found a significant association between RDW and all cause mortality in CABG, and showed for the first time, to our knowledge, that this remained significant even in the presence of other powerful markers, such as EuroScore, whereas hemoglobin was not an independent predictor when RDW was in the model. We found a graded, independent association between baseline RDW level and the risk of all-cause death. Higher levels of baseline RDW (RDW > 14.6) were associated with increased risk of all-cause death. This association remained significant even after adjustment for a wide variety of clinically relevant covariates. These covariates included not only important laboratory and clinical parameters, but also operative and post operative variables which are known to be powerful determinants of mortality. Recently, RDW has been demonstrated to be associated also with cardiovascular and pulmonary diseases (,5). In the context of cardiac diseases, RDW retains remarkably strong prognostic power in chronic heart failure and coronary artery disease (,6). Initially, Felker et al. showed that increased RDW was a strong independent predictor of outcome in patients with chronic heart failure (6). Tonelli et al. reported findings from a randomized controlled trial of patients with coronary artery disease and indicated that mortality was twice as likely in patients with an RDW > 1.8% compared to those with an RDW < 12.6% (4). Several studies have shown the relation between RDW and coronary artery disease (1,7,8). Sandip et al. showed that a higher RDW was a powerful independent predictor of future coronary artery disease risk (). Zorlu et al. showed that RDW value was an independent predictor of early mortality in patients with acute pulmonary embolism due to any reason (5). However, there is no report about RDW-CABG mortality relation. Thus, we studied the effect of RDW on late mortality of CABG. The mechanism by which elevated values of RDW are associated with increased mortality is unknown. Identification of a putative mechanism is hampered by the lack of epidemiological studies demonstrating factors that are associated with anisocytosis. Overtly elevated RDW may represent nutritional deficiency (such as iron deficiency anemia, vitamin B 12 and folic acid deficiency) or recent blood transfusion (9-12). Therefore, we do not think that either of these is a plausible explanation for our findings, although we did not directly assess nutritional status. The presence of systemic atherosclerosis is associated with a low-grade systemic inflammatory response in which leucocytes play a key role. Consequently, inflammatory markers such as C-reactive protein correlate with outcome in patients with atherosclerotic disease (1,14). We speculate that higher levels of RDW may reflect a chronic background inflammatory state, which is associated with adverse clinical outcomes. In inflammatory state, cytokines might affect bone marrow function; and, erythrocyte maturation, induced by erythropoietin, is inhibited and RDW therefore becomes elevated (5,15). Elevated levels of RDW could show the inflammation due to the perioperative myocardial injury. Certainly, perioperative myocardial damage is associated with adverse clinical outcomes. Likewise, cardiopulmonary bypass itself is associated with inflammatory state which may accentuate the effects of elevated preoperative levels which is known to be associated with longterm adverse outcome (16-18). However, these hypotheses will require confirmation in future studies, and more work is needed to explore determinants of RDW in populations with cardiovascular disease. Study Strengths and Limitations The strength of our study is that as our patients have severe coronary artery disease, effect of coronary atherosclerosis is more likely to be manifested at the results. The limitations of our study include the possibility of selection bias, the relatively small number of patients with a highly prevalent disease, lack of data for other adverse outcomes during the follow-up period (heart failure, myocardial infarction, the need for revascularization subsequently and stroke), and the possibility of missing medical records to assess the survival status (however, our mortality rate is similar to that in the literature). Data are also lacking regarding pre and postoperative medication, which may have influenced the outcome of patients and possibly the RDW itself. Lastly, our analysis is retrospective in nature and may be only viewed as hypoth- 5

Preoperative Red Cell Distribution Width as a Predictor of Mortality in Patients After Coronary Artery Bypass Grafting Koroner Arter Baypas Cerrahisi Sonrası Hastalarda Mortalite Belirteci Olarak Preoperatif Kırmızı Küre Dağılım Hacmi esis-generating; prospective data regarding the prognostic value of RDW in patients with CABG are awaited. In conclusion, we demonstrate an independent relation between preoperative higher levels of RDW and all-cause death in CABG. This prognostic utility is independent of other well-recognized individual risk factors and the Euro- SCORE. It appears that RDW > 14.6 holds considerable promise as a powerful predictor of survival after CABG; particularly attractive is that these data are widely available (as a part of the complete blood count) to the clinician at no extra cost. Further studies are required to determine the explanation for the association between RDW and adverse clinical outcomes. ConflIct of Interest None declared. REFERENCES 1. Bridgewater B, Grayson AD, Jackson M, Brooks N, Grotte GJ, Keenan DJ, et al. Surgeon specific mortality in adult cardiac surgery: comparison between crude and risk stratified data. BMJ 200;27:1-7. 2. Van Kimmenade RR, Mohammed AA, Uthamalingam S, van der Meer P, Felker GM, Januzzi JL Jr.Red blood cell distribution width and 1-year mortality in acute heart failure. European Journal of Heart Failure 2010;12:129-6.. Zalawadiya SK, Veeranna V, Niraj A, Pradhan J, Afonso L. Red cell distribution width and risk of coronary heart disease events. Am J Cardiol 2010;106:988-9. 4. Tonelli M, Sacks F, Arnold M, Moye L, Davis B, Pfeffer M. Relation between red blood cell distribution width and cardiovascular event rate in people with coronary disease. Circulation 2008;117:16-8. 5. Zorlu A, Bektasoglu G, Kukul Guven FM, Dogan OT, Gucuk E, et al. MB. Usefulness of admission red cell distribution width as predictor of earlymortality in patients with acute pulmonary embolism. Am J Cardiol 2007;:40-7. 6. Felker GM, Allen LA, Pocock SJ, Shaw LK, McMurray JJ, Preffer MA, et al. Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. J Am Coll Cardiol 2007;50:40-7. 7. Cavusoglu E, Chopra V, Gupta A, Choski PU, Ruwende C, Yanamadala S, et al. Relation between red blood cell distribution width (RDW) and all-cause mortality at two years in an unselected population referred for coronary angiography. Int J Cardiol 2010;141:141-6. 8. Fukuta H, Ohte N, Mukai S, Saeki T, Asada K, Wakami K, et al. Elevated plasma levels of B-type natriuretic peptide but not C-reactive protein are associated with higher red cell distribution width in patients with coronary artery disease. Int Heart J 2009;50:01-12. 9. Karnad A, Poskitt TR, The automated complete blood cell count. Arch Intern Med 1985;145:1270-2. 10. Thompson WG, Meola T, Lipkin M Jr, Freedman ML. Red cell distribution width, mean corpuscular volume, and transferrin saturation in the diagnosis of iron deficiency. Arch Intern Med 1988;148:2128-0. 11. Comeaux L, Fife DJ, McKenzie SB. Instructor s Guide for Clinical Laboratory Hematology. Upper Saddle River, New Jersey: Pearson/Prentice-Hall, 2004. 12. Pascual-Figal DA, Bonaque JC, Redondo B, Caro C, Manzano- Fernandez S, Sánchez-Mas J, et al. Red blood cell distribution width predicts long-term outcome regardless of anaemia status in acute heart failure patients. Eur J Heart Fail 2009;11:840-6. 1. Hampole CV, Mehrotra AK, Thenappan T, Gomberg-Maitland M, Shah SJ. Usefulness of red cell distribution width as a prognostic marker in pulmonary hypertension. Am J Cardiol 2009;104:868-72. 14. Mautner GC, Mautner SL, Roberts WC. Amounts of coronary arterial narrowing by atherosclerotic plaque at necropsy in patients with lower extremity amputation. Am J Cardiol 1992;70:1147-51. 15. Pereira IA, Borba EF. The role of inflammation, humoral and cell mediated autoimmunity in the pathogenesis of atherosclerosis. Swiss Med Wkly 2008;18:54-9. 16. Croal BL, Hillis GS, Gibson PH, Fazal MT, El-Shafei H, Gibson G, et al. The relationship between post-operative cardiac troponin I levels and outcome from cardiac surgery. Circulation 2006;114:1468-75. 17. Gasz B, Lenard L, Benko L, Borsiczky B, Szanto Z, Lantos J, et al. Expression of CD97 and adhesion molecules on circulating leukocytes in patients undergoing coronary artery bypass surgery. Eur Surg Res 2005;7:281-9. 18. Bagger JP, Zindrou D, Taylor KM. Leukocyte count: a risk factor for coronary artery bypass graft mortality. Am J Med 200;115:660-. 6